Showing results (441-450 of 533) with videos related to
Sort By:
Pageof 54
The Journal of Headache and Pain|June 13, 2026
Consistency of response to rimegepant for the acute treatment of migraine among real-world users - findings from the prospective observational CONFIDENCE studyRichard B Lipton, Lucy Abraham, Alexandre Urani, et al.Cephalalgia : an International Journal of Headache|September 21, 2019
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adultsPeter J Goadsby, Stewart J Tepper, Paul B Watkins, et al.JAMA|May 26, 2018
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical TrialDavid W Dodick, Stephen D Silberstein, Marcelo E Bigal, et al.Nature Reviews. Disease Primers|January 14, 2022
MigraineMichel D Ferrari, Peter J Goadsby, Rami Burstein, et al.Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.Brain : a Journal of Neurology|June 22, 2012
Assessing the risk of central post-stroke pain of thalamic origin by lesion mappingTill Sprenger, Christian L Seifert, Michael Valet, et al.European Journal of Neurology|July 29, 2023
European Academy of Neurology guidelines on the treatment of cluster headacheArne May, Stefan Evers, Peter J Goadsby, et al.European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.Cephalalgia : an International Journal of Headache|December 12, 2018
Cortical abnormalities in episodic migraine: A multi-center 3T MRI studyStefano Magon, Arne May, Anne Stankewitz, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 30, 2021
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY studyMichel Dominique Ferrari, Uwe Reuter, Peter J Goadsby, et al.Pageof 54